Join Growin Stock Community!
Beta
Back to NVO.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
operating-expenses-chart

NVO Operating Expenses

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

In Q1'26, Novo Nordisk's (NVO) total operating expenses reached $23.5B USD, comprising $10.3B USD in R&D expenses and $13.2B USD in SG&A expenses, reflecting a decline from the prior quarter's $32.1B USD total. From Q2'23 to Q1'26, R&D expenses exhibited volatile growth, surging from $7.1B USD to a peak of $16.2B USD in Q2'24 before stabilizing around $10-15B USD, while SG&A expenses showed steady increases from $15.4B USD to highs near $20B USD in Q4'24 and Q2'25, with overall operating expenses trending upward by approximately 50% over the period amid fluctuating quarterly patterns.